Enclomiphene vs Rosuvastatin
Well Studied vs FDA Approved
avoid Mechanism-based · 64% Both Enclomiphene and Rosuvastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Enclomiphene Rosuvastatin
Weight 405.96 Da 481.54 Da
Half-life ~10 hours ~19 hours
Type Trans-isomer of clomifene (selective estrogen receptor modulator) Synthetic statin (C22H28FN3O6S-Ca)
Key Benefits
Enclomiphene
01 Raises endogenous testosterone by stimulating the HPTA axis
02 Preserves fertility and spermatogenesis (unlike exogenous testosterone)
03 No estrogenic agonist activity (unlike racemic clomifene/Clomid)
04 Oral dosing with no injections required
05 Does not suppress the HPTA or cause testicular atrophy
06 Effective for post-cycle therapy and secondary hypogonadism
07 Well-tolerated with a favorable side effect profile
Rosuvastatin
01 Most potent statin available, with LDL reductions of 45-63% depending on dose
02 Long half-life (19 hours) allows flexible once-daily dosing at any time of day
03 Effective at counteracting AAS-induced lipid disturbances, particularly elevated LDL
04 Significant reduction in high-sensitivity CRP (30-50%), indicating anti-inflammatory benefit
05 Hydrophilic structure provides hepatic selectivity with potentially fewer muscle side effects
06 Raises HDL cholesterol by 8-14%, partially offsetting AAS-mediated HDL suppression
07 Proven cardiovascular event and mortality reduction in large-scale clinical trials
08 Reduces triglycerides by 10-35%, beneficial during bulking phases or when using compounds that elevate TG
Side Effects
Enclomiphene
Headache
Nausea or mild gastrointestinal discomfort
Hot flashes or flushing
Mood changes (irritability or emotional sensitivity)
Fatigue during initial adjustment
Rosuvastatin
Muscle pain and myalgia (5-10% of users) -- the most frequently reported complaint, ranging from mild soreness to significant discomfort
Headache
Nausea and abdominal discomfort
Weakness or fatigue
Constipation or diarrhea
Contraindications
Known hypersensitivity to clomifene or enclomiphene
Pre-existing liver disease or significantly elevated liver enzymes
Active or history of thromboembolic disorders
Pregnancy or women who may become pregnant (teratogenic risk)
Primary hypogonadism (testicular failure -- enclomiphene requires functional testes)
Pituitary tumors or undiagnosed pituitary pathology
Active liver disease or unexplained persistent elevations in hepatic transaminases
Known hypersensitivity to rosuvastatin or any excipients
Pregnancy and breastfeeding (Category X -- statins are teratogenic)
Concomitant use with cyclosporine (at all doses of rosuvastatin)
Severe renal impairment (eGFR <30 mL/min) for doses above 10 mg
Research Evidence
Enclomiphene Rosuvastatin
Status Well Studied FDA Approved
References 5 studies 4 studies
Latest — 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.